Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OSI DPP-IV Inhibitor Is A “Sensible Approach” To Diabetes Dosing, Firm Says

Executive Summary

The meal-related dosing schedule of OSI Pharmaceuticals' type 2 diabetes candidate PSN9301 could lead to better patient compliance, the company said

You may also be interested in...

Novartis Takes Aim: Galvus Promotions To Target Other Classes, Not Januvia

Novartis' strategy for launching its dipeptidyl peptidase IV inhibitor Galvus will be to position the antidiabetic as an option against other existing therapeutic classes, not head-to-head against Merck's DPP-IV Januvia

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts